Gilead to stop late-stage study of COVID-19 treatment

1 minute read

The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo

Register now for FREE unlimited access to Reuters.com

April 12 (Reuters) - Gilead Sciences Inc (GILD.O) said on Monday it had decided to stop a late-stage trial of its intravenous treatment, Veklury, in high-risk non-hospitalized patients with COVID-19.

The company said it no longer believes that developing a multiple day injection that requires administration in a healthcare setting addresses an unmet need for non-hospitalized patients.

The decision to stop the study is not due to efficacy or safety concerns, Gilead said.

Register now for FREE unlimited access to Reuters.com
Reporting by Dania Nadeem in Bengaluru; Editing by Anil D'Silva

Our Standards: The Thomson Reuters Trust Principles.